Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caron A Jacobson

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.
Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.
Blood|February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
Blood|April 18, 2024
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicityFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
The New England Journal of Medicine|December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L Locke, David B Miklos, Caron A Jacobson, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
Blood|September 2, 2020
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphomaGabriel K Griffin, Jason L Weirather, Margaretha G M Roemer, et al.
JCO Oncology Practice|September 8, 2023
Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow TestingAli AlJabban, Henry Paik, Jon C Aster, et al.
JAMA|August 8, 2023
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical TrialTomas G Neilan, Thiago Quinaglia, Takeshi Onoue, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.
Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.
Blood|February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
Blood|April 18, 2024
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicityFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
The New England Journal of Medicine|December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L Locke, David B Miklos, Caron A Jacobson, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
Blood|September 2, 2020
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphomaGabriel K Griffin, Jason L Weirather, Margaretha G M Roemer, et al.
JCO Oncology Practice|September 8, 2023
Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow TestingAli AlJabban, Henry Paik, Jon C Aster, et al.
JAMA|August 8, 2023
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical TrialTomas G Neilan, Thiago Quinaglia, Takeshi Onoue, et al.
Pageof 14